Home・Aandelen Lijst・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Open

SectorGezondheidszorg

49.74 9.61

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

44.21

Max

48.35

Belangrijke statistieken
By Trading Economics
Inkomsten	2.8M -13M
Verkoop	-15M 151M
EPS	0.07
Winstmarge	-8.93
Werknemers	1,178
EBITDA	19M -937K

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	-5.7% downside

Dividenden
By Acuity
Volgende Winsten	5 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.2B 6B
Vorige openingsprijs	40.13
Vorige sluitingsprijs	49.74

Nieuwssentiment

By Acuity

100%

329 / 340 Rangschikking in Healthcare

10X Genomics Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 aug 2026, 23:02 UTC

News

10X Genomics reported a net loss of $17.9 million for Q2, with shares trading lower in after-market hours amid concerns over an operating loss.

5 aug 2026, 19:26 UTC

Correlated Moves

News

10X Genomics Inc shares are lower amid broader market declines. The company reported $150.8 million in revenue last quarter, reflecting a year-on-year decline.

3 aug 2026, 19:36 UTC

Correlated Moves

Social Media

10X Genomics Inc reached a new 52-week high, reflecting strong market activity and positive sentiment in the genomics sector. Shares are higher since Friday's close.

31 jul 2026, 19:36 UTC

Correlated Moves

Social Media

10X Genomics shares are lower today, continuing a decline since Thursday's close. The Russell 2000 Index also reflects broader market weakness.

30 jul 2026, 17:06 UTC

Correlated Moves

10X Genomics Inc is higher today, supported by broader market trends and a significant rise since Wednesday's close. The stock peaked intraday with notable gains.

29 jul 2026, 19:27 UTC

Macro Event

News

10X Genomics Inc announced a collaboration with Lausanne University Hospital to enhance cancer diagnostics. Shares are higher since Tuesday's close, reflecting positive sentiment.

28 jul 2026, 23:11 UTC

10X Genomics Inc. is trading higher in after-market hours, maintaining a position near its one-month range's upper end. No specific news was identified for the move.

27 jul 2026, 18:36 UTC

10X Genomics Inc shares are lower today, with no specific news identified. The stock remains near the upper end of its one-month range.

24 jul 2026, 16:26 UTC

10X Genomics Inc shares declined during Friday's session, hitting a session low before a slight recovery. The stock remains above its 20-day moving average.

23 jul 2026, 23:26 UTC

Correlated Moves

10X Genomics Inc shares declined in after-market trading, mirroring a broader market trend. The stock remains near the upper end of its one-month range.

22 jul 2026, 19:51 UTC

Correlated Moves

10X Genomics Inc reports a first-quarter net loss of -$34 million, with revenue falling to $47 million, as shares trade lower amid broader market declines.

21 jul 2026, 19:53 UTC

Correlated Moves

Positive investor sentiment drives 10X Genomics Inc higher amid a broader market recovery, reflecting gains since Monday's close and aligning with small-cap stock interest.

20 jul 2026, 19:16 UTC

News

Correlated Moves

10X Genomics Inc. shares are lower as a report cites only 1.1% annual sales growth and ineffective growth strategies amid a declining Life Sciences Tools sector.

Peer Vergelijking

Prijswijziging

10X Genomics Inc (Class A) Prognose

Koersdoel

By TipRanks

-5.7% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 43 USD -5.7%

Hoogste 53 USD

Laagste 23 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor 10X Genomics Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

Buy

Hold

Sell

Gebaseerd op 13 analisten die aandelenratings hebben gegeven aan 10X Genomics Inc (Class A) - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.